Concepedia

V. Atduev

VA

2

Publications

29

Citations

2

H-Index

2022

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Institut Gustave Roussy

V. Atduev is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in urology, cancer therapeutics, and medicine.

Top concepts

Publications per year

2022–2025

2

Publications

2

LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study

Christof Vulsteke, H. Kaimakliotis, Pongwut Danchaivijitr et al. · Annals of Oncology · 2025 · 16 citations · Full text

1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Albiges, H.P. Gurney, V. Atduev et al. · Annals of Oncology · 2022 · 13 citations

, , +6

Rows per page

1–2 of 2